Eli Lilly details Phase 3 results for triple-agonist retatrutide, showing large weight and cardiometabolic gains
Eli Lilly released supplemental Phase 3 findings for retatrutide, a triple hormone receptor agonist for weight management. In the 80-week TRIUMPH-1 study, the 12 mg dose produced an average 28.3% body weight reduction and substantial rates of obesity remission by BMI. Nested analyses showed marked improvements in knee osteoarthritis pain and obstru…